Patents by Inventor Ole Eriksen

Ole Eriksen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9943599
    Abstract: The present inventors have shown that electroporation with calcium ions are efficient on cutaneous and subcutaneous nodules. In particular the present inventors here disclose that a solution comprising calcium ions (Ca2+) with a concentration of at least 0.1 M is extremely useful in a method of treating a neoplasm, such as cancer with means for causing transient permeabilization of the cell membranes of at least part of the neoplasm before, during and/or after administration of said solution, wherein said solution is administered with a ratio of 0.2 to 0.8 of the volume of said part of the neoplasm.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: April 17, 2018
    Assignee: HERLEV HOSPITAL
    Inventors: Karen Julie Gehl, Stine Krog Frandsen, Jens Ole Eriksen, Hanne Margrethe Gissel Hyldkrog, Pernille Højman Jensen
  • Publication number: 20150065946
    Abstract: The present inventors have shown that electroporation with calcium ions are efficient on cutaneous and subcutaneous nodules. In particular the present inventors here disclose that a solution comprising calcium ions (Ca2+) with a concentration of at least 0.1 M is extremely useful in a method of treating a neoplasm, such as cancer with means for causing transient permeabilisation of the cell membranes of at least part of the neoplasm before, during and/or after administration of said solution, wherein said solution is administered with a ratio of 0.2 to 0.8 of the volume of said part of the neoplasm.
    Type: Application
    Filed: December 21, 2012
    Publication date: March 5, 2015
    Inventors: Karen Julie Gehl, Stine Krog Frandsen, Jens Ole Eriksen, Hanne Margrethe Gissel Hyldkrog, Pernille Højman Jensen
  • Publication number: 20070225248
    Abstract: The present invention relates to oral dosage forms of certain long chain saturated and monounsaturated fatty acid derivatives of 2?,2?-difluorodeoxycytidine (Gemcitabine). In particular, the present invention relates to the use of the said gemcitabine derivatives or a pharmaceutical acceptable salt thereof for preparing an oral dosage form ameliorating compliance in treatment of cancer.
    Type: Application
    Filed: March 21, 2006
    Publication date: September 27, 2007
    Applicant: Clavis Pharma AS
    Inventors: Finn Myhren, Marit Sandvold, Ole Eriksen
  • Publication number: 20070135436
    Abstract: This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives are referred to as “Compounds of formula I” herein. Compounds of formula I can be used in the treatment of a cancerous disease. Treatment of both solid tumours and haematological cancers such as leukaemias, lymphomas and multiple myelomas are included.
    Type: Application
    Filed: December 19, 2005
    Publication date: June 14, 2007
    Applicant: Clavis Pharma AS
    Inventors: Finn Myhren, Marit Sandvold, Steinar Hagen, Ole Eriksen